Braveheart Bio Reports 52-Week HCM Drug Study Results

In a 42-patient open-label extension, HRS/BHB-1893 improved exercise capacity and symptom scores at Week 52; 79% had a Valsalva LVOT gradient below 30 mmHg. No on-treatment severe or serious adverse events were reported.